Hangzhou Sciwind Biosciences Co Ltd, a China-based, commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, announced on Sunday that key data from a head-to-head study (SLIMMER-UP-SWITCH) evaluating ecnoglutide versus semaglutide was presented as a Late-Breaking abstract at the 86th Scientific Sessions of the American Diabetes Association (ADA) 2026.

According to the company, interim analysis results showed that ecnoglutide, the world's first approved cAMP-biased GLP-1 receptor agonist, demonstrated greater weight loss compared to semaglutide, with a 35% greater reduction in body weight, a 20% greater reduction in waist circumference at Week 20, and nearly twice as many patients achieving greater than 10% body weight loss.

Professor Linong Ji, director of the Department of Endocrinology at Peking University People's Hospital, said that this study provides the first direct clinical evidence validating the clinical advantages of the innovative cAMP-biased GLP-1 receptor agonist mechanism. By optimising GLP-1 receptor signal transduction, it delivers superior clinical benefits over traditional GLP-1 receptor agonists, providing high-quality evidence-based medical evidence for the field of weight management.

This study enrolled 163 adult patients with obesity across 17 research centres in China. Participants were randomised 1:1 to receive once-weekly subcutaneous injections of either ecnoglutide or semaglutide at the same maintenance dose of 2.4 mg. The company says that in addition to potent weight loss, ecnoglutide also demonstrated remarkable advantages in improving body circumference. At week 20, the mean reduction in waist circumference from baseline was 10.5 cm in the ecnoglutide group and 8.7 cm in the semaglutide group, representing a 20% greater reduction for ecnoglutide. Improvements in other circumference measures including arm circumference and neck circumference were also superior to those of semaglutide.

Ecnoglutide is a cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences for obesity and related metabolic diseases. Pfizer has exclusive commercialisation rights for Sciwind's injectible ecnoglutide product in Mainland China.